AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government’s strategy.
As reported by Reuters this week, Prime Minister Theresa May’s office has asked companies listed in the blue-chip FTSE 100 index to put their name to a public letter welcoming the government’s efforts to make Brexit a success.
“The reason I didn’t sign is that I felt there are so many areas that are still uncertain. How can we support something that we don’t really understand fully?” Soriot told Reuters on the sidelines of a cancer conference in Madrid.
Executives at several companies have said privately that the request went down badly with many large corporations but they have been reluctant to comment publicly.
Soriot said his refusal to sign did not mean the drugmaker disagreed with Britain’s decision to leave the European Union, adding that it could have some positive aspects if it went hand-in-hand with increased support for the UK life sciences sector.
But the deep uncertainty about future terms of trade just 18 months before Brexit happens in March 2019 means exports of medicines could be hampered, he said.
“What is starting to worry me, I must say, is the potential for the one thing I didn’t think would happen which is a hard Brexit,” he said.
“If there is no extension we will be left in limbo because the UK will come out of Europe and we will have no trade agreements.”
Britain’s second-biggest pharmaceuticals company makes a large amount of products in the north of England, including the cancer drug Zoladex, sales of which are increasing rapidly in China and other countries around the world.
“We need to know that is not going to be disrupted because right now we are exporting under a trade agreement between the EU and China,” Soriot said.
Many companies fear that Britain’s move to leave the world’s largest trading bloc will increase bureaucracy, drive up costs and eat into profitability.
The public letter, which May’s advisers wanted Soriot and other business leaders to sign, states that signatories are confident that “global Britain has the potential to become one of the most productive economies of the 21st century”.
By Ben Hirschler
Source: Reuters
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
